Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 12;14(1):104.
doi: 10.1186/s13550-024-01165-8.

Influence of fasting prior to 18F-rhPSMA-7.3 (Flotufolastat F-18) PET/CT on biodistribution and tumor uptake

Sonia Grigorascu  1 , Thomas Langbein  2 , Isabel Rauscher  2 , Calogero D'Alessandria  2 , Tobias Maurer  3 , Türkay Hekimsoy  2 , Wolfgang A Weber  2 , Matthias Eiber  2
Affiliations

Influence of fasting prior to 18F-rhPSMA-7.3 (Flotufolastat F-18) PET/CT on biodistribution and tumor uptake

Sonia Grigorascu et al. EJNMMI Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations Ethics approval and consent to participate The analysis was approved by the Ethics Committee of the Technical University Munich (permit 99–19 S), and is in accordance with the principles of the Declaration of Helsinki. The requirement to obtain informed consent was waived. Consent for publication Not applicable. Competing interests ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. WW is on the advisory boards and receives compensation from Blue Earth Diagnostics, ITG and Pentixapharm. He has received research support from Blue Earth Diagnostics, BMS, and Pentixapharm. He is also an advisory editor for EJNMMI Research. IR is an associate editor for EJNMMI Research. No other potential conflicts of interest relevant to this article exist. The other authors, SG, TL, TH, CDA and TM, have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Biodistribution by organ
See this image and copyright information in PMC

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. - PubMed
    1. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16. - PubMed
    1. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate Cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63. - PMC - PubMed
    1. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74. - PubMed
    1. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006;25(6):1375–84. - PMC - PubMed

LinkOut - more resources